Development
Shanghai Henlius's HLX3902 trispecific antibody enters Phase I trial for advanced solid tumours
Shanghai Henlius Biotech, the HKEX-listed Chinese biopharmaceutical company, has registered a first-in-human Phase I clinical trial for HLX3902, a...
Jade Biosciences' anti-BAFF-R antibody entering Phase I for rheumatoid arthritis
Jade Biosciences, a NASDAQ-listed clinical-stage company (ticker: JBIO), has registered a first-in-human Phase I trial of JADE201, an afucosylated,...
Freya Bio's live biotherapeutic shows promise in Phase I trial for IVF embryo implantation failure
Freya Biosciences reported Phase I data for FB301, a defined multi-strain Lactobacillus live biotherapeutic, showing that the vaginally administered product...
Eli Lilly's orforglipron set for approval filing in diabetes after positive Phase III results
Eli Lilly (NYSE: LLY) reported that orforglipron (Foundayo) met its primary cardiovascular safety endpoint in the Phase III ACHIEVE-4 trial, demonstrating...
Bold Therapeutics' Bold-100 shows lower neuropathy rates in Phase I/II FOLFOX combination trial
Bold Therapeutics reported that BOLD-100, its ruthenium-based anticancer agent, was associated with substantially lower rates of oxaliplatin-induced...
AIM ImmunoTech's rintatolimod advances to Phase III trial for pancreatic cancer on positive signals
AIM ImmunoTech (NYSE American: AIM) announced plans to advance rintatolimod (Ampligen) into a Phase III trial for late-stage pancreatic ductal...
Arbutus Biopharma's imdusiran hepatitis B therapy takes FDA Fast Track status
Arbutus Biopharma announced on April 15, 2026 that the US FDA granted Fast Track designation for imdusiran (AB-729) for the treatment of chronic hepatitis B...
Immorna's posts early positive data for in vivo CAR-T in systemic sclerosis
Immorna, a Hangzhou-based clinical-stage biotechnology company, reported early clinical data for JCXH-213, its CD19-targeted in vivo CAR-T candidate, in a...
Amgen terminates Phase I trial of AMG 378 in strategic decision
Amgen Terminates Phase I Trial of AMG 378 Before Primary Completion
Spyre's SPY001 meets primary endpoint in Phase II ulcerative colitis induction trial
Spyre Therapeutics (Nasdaq: SYRE) reported that SPY001, its extended half-life anti-α4β7 antibody, met the primary endpoint in the open-label Part A of the...
GSK's B7-H4 ADC set for 5 Phase III trials in gynecological cancers after strong Phase I
GSK (LSE/NYSE: GSK) reported Phase I data for mocertatug rezetecan, a B7-H4-targeted antibody-drug conjugate, showing confirmed objective response rates of...
BioNTech and DualityBio's trastuzumab pamirtecan hits endpoitn in Phase II for endometrial cancer
BioNTech (Nasdaq: BNTX) and DualityBio reported that trastuzumab pamirtecan met its primary endpoint in a Phase II cohort of 145 patients with...
AbbVie's Elahere demonstrates 62.7% response rate in platinum-sensitive ovarian cancer
AbbVie presented Phase II results for mirvetuximab soravtansine (ELAHERE) in folate receptor alpha (FRα)-positive, recurrent platinum-sensitive ovarian...
SynOx's CSF-1R antibody emactuzumab set for approval filing in TCGT after strong Phase III
SynOx Therapeutics reported that emactuzumab met both primary and secondary endpoints in the Phase III TANGENT study in tenosynovial giant cell tumor, with...
Grand Pharma's SIR-Spheres Y-90 aces endpoints in HCC Phase III
Grand Pharmaceutical Group (HKEX: 00512) announced that the DOORwaY90 trial of SIR-Spheres Y-90 resin microsphere injection in unresectable hepatocellular...
The AllSci Brief
Systematic R&D and deal news. Daily.